Engineering proteins as tools in ADC development and manufacture
In the recent BioPharm International issue in April 2017, Dr Deepan Shah, Orla Protein Technologies’ Head of Protein Engineering, examined some of the challenges faced by drug developers during ADC development. He described how Orla’s protein engineering approach can help to tackle some of these challenges and provide analytical tools that allow faster decision-making during the development process.
There has been a growing interest in antibody-drug conjugates (ADCs) as cancer treatments because of their ability to enhance the selectivity of chemotherapeutic agents while limiting systemic exposure and adverse effects. The development and manufacture of these complex molecules, however, can be a challenge.
Dr Shah explains that the ability of the ADC to 1) bind to its target antigen, 2) become internalized, and 3) release the toxic cargo are all crucial steps that determine the efficacy of the ADC. The first step in this process is the most likely one to be adversely affected by the treatments necessary for ADC production. Organic solvents, pH, and temperature shifts can all cause damage to an antibody.
The industry therefore requires analytical tools that help to test the binding of an antibody to its target during ADC method development and manufacture. Orla’s binding proteins can be used to monitor antibody-binding on a range of platforms including ELISA, Octet, and Biacore allowing drug developers to take decisions more rapidly and helping to optimise their antibodies with minimal adverse effect on the antibody function.
Read the full article under http://www.biopharminternational.com/engineered-proteins-tools-adc-development-and-manufacture